Study on the underlying mechanism of Qianghuo Shengshi Decoction in the treatment of wind-cold-dampness arthralgia type rheumatoid arthritis by integrating systems biology,transcriptomics and experimental validationOA
Background:One of the first hundred traditional Chinese medicines(TCM)formulas administered in China,Qianghuo Shengshi Decoction(QSD)has a positive clinical and therapeutic impact on rheumatoid arthritis(RA).Even so,there is still not enough knowledge on the active ingredients and possible ways that QSDs might work to treat RA.This study systematically investigated the active ingredients and mechanisms of action of QSD for treating wind-cold-dampness arthralgia type RA.Methods:UHPLC-QE-MS and network pharmacology techniques were employed to predict the potential active constituents,targets,and associated signalling pathways.Then,the therapeutic effect of QSD was examined using a wind-cold-dampness arthralgia paralytic RA rat model.Finally,the complex mechanism was comprehensively elucidated by integrating transcriptomics and network pharmacology.The above mechanisms were also verified by molecular docking,immunohistochemistry and Western blot.Results:UHPLC-QE-MS and network pharmacology analysis revealed that ferulic acid,imperatorin,magnolol,quercetin,and scopoletin could be the primary constituents in QSD responsible for its anti-RA effects.Animal experiments showed that QSD can significantly inhibit rat joint swelling degree,decrease the content of serum rheumatoid factor(RF),interleukin(IL)-1β,tumor necrosis factor-alpha(TNF-α),IL-6,and anti-citrullinated protein antibodies(ACPA),and increase the content of IL-4,IL-10 to relieve the clinical symptoms of wind-cold-dampness arthralgia type RA.The mechanistic study showed that QSD may effectively inhibit rat synovial hyperplasia via promoting autophagy and apoptosis of synovial cells by regulating the PI3K/Akt/mTOR signalling pathway.Conclusion:This study identifies key active ingredients in QSD and elucidates its potential mechanism for treating wind-cold-dampness arthralgia type RA,providing a basis for the clinical application of QSD.
Huan Tian;Qing-Rui Qi;Feng Zhao;Qiang-Qiang Fan;Bao-Sen Yue;Kang Yang;Wei-Ying Zhang;Bing-Tao Zhai
Department of Pharmacy,Xi’an Hospital of Traditional Chinese Medicine,Xi’an 710021,ChinaDepartment of Pharmacy,Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou 730050,ChinaDepartment of Pharmacy,Xi’an Hospital of Traditional Chinese Medicine,Xi’an 710021,ChinaShaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research,Shaanxi University of Chinese Medicine,Xianyang 712046,China.Department of Pharmacy,Xi’an Hospital of Traditional Chinese Medicine,Xi’an 710021,ChinaDepartment of Pharmacy,Xi’an Hospital of Traditional Chinese Medicine,Xi’an 710021,ChinaDepartment of Pharmacy,Xi’an Hospital of Traditional Chinese Medicine,Xi’an 710021,ChinaShaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research,Shaanxi University of Chinese Medicine,Xianyang 712046,China.
医药卫生
Qianghuo Shengshi Decoctionwind-cold-dampness arthralgia type rheumatoid arthritisnetwork pharmacologytranscriptomicsPI3K/Akt/mTOR signalling pathway
《Traditional Medicine Research》 2026 (5)
P.40-52,13
the National Natural Science Foundation of China(82204935)the construction project of Zhao Feng National Old Pharmacist Inheritance Studio of State Administration of Traditional Chinese Medicine(National Traditional Chinese Medicine Education Letter[2024]255)the open project of the Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine in Shaanxi Province(KF202302)the project of Xi’an Municipal Bureau of Science and Technology(23YXYJ0042)for financial support.
评论